SCHEMBL29299677

SCHEMBL29299677

CC(C)CCCN1CCN(C(=O)CCCCCNC(=O)CN2CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NAMPT P43490 1/20 0.43
FOLH1 Q04609 11/20 0.42
ALDH1A1 P00352 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
HTR7 P34969 2/20 0.39
HTR1A P08908 1/20 0.39
CACNA1F O60840 1/20 0.36
DRD1 P21728 1/20 0.36
DRD4 P21917 1/20 0.36
DRD5 P21918 1/20 0.36
HRH2 P25021 1/20 0.36
ADRA1D P25100 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36
HRH1 P35367 1/20 0.36
ADRA1B P35368 1/20 0.36
OPRM1 P35372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29300481 0.87 GNAI3 (0.43) TP53SMN1; SMN2FOLH1SIGMAR1HTR7
SCHEMBL29299819 0.87 FOLH1 (0.51) TP53SMN1; SMN2NAMPTFOLH1
SCHEMBL29299828 0.87 FOLH1 (0.48) TP53SMN1; SMN2NAMPTFOLH1ALDH1A1
SCHEMBL29300569 0.87 HTR7 (0.39) TP53SMN1; SMN2NAMPTALDH1A1SIGMAR1
SCHEMBL29299679 0.86 ALDH1A1 (0.45) TP53SMN1; SMN2NAMPTFOLH1ALDH1A1
SCHEMBL254152 0.84 SMN1; SMN2 (0.48) TP53SMN1; SMN2FOLH1ALDH1A1SIGMAR1
SCHEMBL29299673 0.83 FOLH1 (0.45) TP53SMN1; SMN2NAMPTFOLH1ALDH1A1
SCHEMBL23824133 0.83 SMN1; SMN2 (0.49) TP53SMN1; SMN2FOLH1ALDH1A1SIGMAR1
SCHEMBL29299601 0.82 HTR7 (0.41) TP53SMN1; SMN2NAMPTALDH1A1SIGMAR1
SCHEMBL29299829 0.82 SMN1; SMN2 (0.46) TP53SMN1; SMN2NAMPTFOLH1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R TP53 517/4885SMN1; SMN2 3725/4885NAMPT 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.